Nakayama N, Yamashita K, Tanaka T, Kawamata H, Ooki A, Sato T, Nakamura T, Watanabe M
Department of Surgery, Kitasato University School of Medicine, Asamizodai 2-1-1, Minami-ku, Sagamihara, Kanagawa, 252-0380, Japan.
Clin Exp Metastasis. 2016 Jan;33(1):3-13. doi: 10.1007/s10585-015-9749-7. Epub 2015 Nov 12.
PRL-3 genomic copy number is increased in colorectal cancer (CRC), and PRL-3 expression is closely associated with lymph node and liver metastasis of CRC. However, the clinical significance of PRL-3 genomic gain for CRC remains obscure. Here, PRL-3 genomic status in 109 primary CRC tumors and in 44 CRC tumors that had metastasized to the liver, was quantified using real time PCR. Association of PRL-3 genomic status with clinicopathological factors and prognosis was assessed in detail. PRL-3 genomic gain was identified in 31 primary CRC (27.4 %) and was more frequently seen in stage III than in stage II (p = 0.025). Among the clinicopathological factors assessed, PRL-3 genomic gain was significantly associated with poorly differentiated histology (p = 0.0039). Moreover, CRC patients with PRL-3 genomic gain exhibited poorer prognosis than those with no gain in stage II-IV CRC (p = 0.017). PRL-3 genomic gain was identified in 18 (41 %) of the liver metastasis tumors, and this frequency of gain was significantly increased as compared to that of the corresponding primary CRCs (11 %) (p = 0.001). Our findings suggested that PRL-3 genomic gain may represent an aggressive phenotype of primary CRC, and may associate with liver metastasis.
结直肠癌（CRC）中PRL - 3基因拷贝数增加，且PRL - 3表达与CRC的淋巴结及肝转移密切相关。然而，PRL - 3基因增益对CRC的临床意义仍不清楚。在此，采用实时PCR对109例原发性CRC肿瘤及44例已发生肝转移的CRC肿瘤中的PRL - 3基因状态进行定量分析。详细评估PRL - 3基因状态与临床病理因素及预后的相关性。在31例原发性CRC（27.4%）中检测到PRL - 3基因增益，且在III期比II期更常见（p = 0.025）。在评估的临床病理因素中，PRL - 3基因增益与低分化组织学显著相关（p = 0.0039）。此外，在II - IV期CRC中，PRL - 3基因增益的患者预后比无增益的患者差（p = 0.017）。在18例（41%）肝转移肿瘤中检测到PRL - 3基因增益，与相应原发性CRC（11%）相比，这种增益频率显著增加（p = 0.001）。我们的研究结果表明，PRL - 3基因增益可能代表原发性CRC的侵袭性表型，并可能与肝转移相关。
